Dr. Yardley on HERMIONE-2 Trial for HER2+ Breast Cancer

Denise A. Yardley, MD
Published: Monday, Jun 20, 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open-label trial comparing MM-302 plus trastuzumab (Herceptin) with chemotherapy plus trastuzumab in patients with anthracycline-naïve, locally advanced, HER2-positive breast cancer who were previously treated with pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1).

This ongoing trial is addressing an unmet need, as there is a rising incidence of HER2-positive patients who are anthracycline-naive, Yardley explains. In the study, patients in the MM-302 arm receive the novel antibody-drug conjugate once every 3 weeks.

The primary endpoint of the study, she adds, is progression-free survival. The safety of MM-302 in combination with trastuzumab will also be explored. 

 
Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open-label trial comparing MM-302 plus trastuzumab (Herceptin) with chemotherapy plus trastuzumab in patients with anthracycline-naïve, locally advanced, HER2-positive breast cancer who were previously treated with pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1).

This ongoing trial is addressing an unmet need, as there is a rising incidence of HER2-positive patients who are anthracycline-naive, Yardley explains. In the study, patients in the MM-302 arm receive the novel antibody-drug conjugate once every 3 weeks.

The primary endpoint of the study, she adds, is progression-free survival. The safety of MM-302 in combination with trastuzumab will also be explored. 

 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x